2 results match your criteria: "Vall d'Hebron Barcelona Hospital Campus. CIBER de Enfermedades Respiratorias (CIBERES)[Affiliation]"
Risk of lung disease in the PI*SS genotype of alpha-1 antitrypsin: an EARCO research project.
Respir Res
June 2024
Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), Vall d'Hebron Barcelona Hospital Campus. CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
Article Synopsis
- The study investigates the PI*SS genotype's risk for lung disease in individuals with alpha-1 antitrypsin deficiency (AATD) and compares it to the more common PI*ZZ and PI*SZ genotypes.
- Using data from 1,007 participants, results indicate that individuals with the PI*SS genotype have a lower prevalence of lung diseases like COPD and emphysema compared to PI*ZZ patients, but similar rates to those with the PI*SZ genotype.
- The findings suggest that while PI*SS is linked to lower lung disease risk than PI*ZZ, it does not show a significant difference when compared to PI*SZ, despite higher serum AAT levels in the former group.
Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain.
Arch Bronconeumol (Engl Ed)
March 2021
Pneumology Department, Hospital Universitari Vall d́Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus. CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; Medicine Department, Autonomous University of Barcelona (UAB), Bellaterra (Cerdanyola del Vallés), Barcelona, Spain. Electronic address:
Background: Recent data from real world clinical practices on the use of Triple Therapy (TT) in patients with COPD are scarce.
Methods: Observational population-based study with longitudinal follow-up in patients with COPD identified in a primary care electronic medical records database in Catalonia, covering 80% of the general population. The aims were to characterize COPD patients who initiated TT and to describe treatment pathways before and after TT initiation.